News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

XDx, Inc. Announces Highmark’s Coverage of AlloMap® for Monitoring Heart Transplant Rejection


11/8/2011 9:12:59 AM

BRISBANE, Calif.--(BUSINESS WIRE)--XDx, Inc., a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value non-invasive diagnostic tests to monitor immune-mediated conditions, today announced that Highmark Inc., an independent licensee of the Blue Cross Blue Shield Association, is now covering AlloMap® for its beneficiaries. Highmark considers AlloMap “medically necessary” for monitoring heart transplant rejection, recognizing the clinical benefits of a non-invasive method for managing rejection in stable heart transplant recipients. AlloMap now is covered for approximately two-thirds of the United States heart transplant population.

Read at BioSpace.com

comments powered by Disqus
XDx, Inc.
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES